title: Arsenic in leukemia: a RSKy business.
abstract: It has been known for many years that arsenic trioxide (As 2O 3; ATO) is an effective therapy for acute promyelocytic leukemia but has little activity against other forms of the disease. ATO has diverse modes of action, but is well known to generate high levels of reactive oxygen species in cells which are believed to be causal in many of its biologic actions. ROS can both activate and suppress signaling through multiple intracellular pathways based on the amount and duration of ROS production. As the basal activity of the MEK1/2-ERK1/2 pathway is often high in acute myeloid leukemias, and that ATO is known to stimulate MEK1/2-ERK1/2 signaling in leukemia, the authors investigated whether knock down of the downstream effector of ERK1/2, RSK1, could enhance the anti-leukemic activity of ATO.
authors.affiliation: Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Dent
mesh_terms: D001152:Arsenicals / Q000494:pharmacology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D010087:Oxides / Q000494:pharmacology*; D038744:Ribosomal Protein S6 Kinases, 90-kDa / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D001152:Arsenicals; D010087:Oxides; D038744:Ribosomal Protein S6 Kinases, 90-kDa
keywords: RSK signaling; arsenic trioxide; kinase; leukemia; mRNA translation; mTOR
references.citation: Cancer Biol Ther. 2003 Nov-Dec;2(6):670-6
references.pmid: 14688474
references.citation: J Biol Chem. 2001 May 4;276(18):14572-80
references.pmid: 11278279
references.citation: Mol Pharmacol. 2011 Mar;79(3):368-80
references.pmid: 21119025
references.citation: Cancer Biol Ther. 2013 May;14(5):411-6
references.pmid: 23377826
references.citation: Cancer Biol Ther. 2002 Mar-Apr;1(2):168-76
references.pmid: 12170777
references.citation: Leukemia. 2005 Feb;19(2):234-44
references.pmid: 15538402
references.citation: Cancer Biol Ther. 2005 Nov;4(11):1195-202
references.pmid: 16177566
references.citation: Cancer Biol Ther. 2002 May-Jun;1(3):243-53
references.pmid: 12432271
references.citation: Curr Opin Hematol. 2005 Jan;12(1):1-6
references.pmid: 15604884